Skip to main content
An official website of the United States government
Email

Capivasertib (AZD5363)

Agent Description

Capivasertib is a potent, selective inhibitor of the kinase activity of serine/threonine specific protein kinase (AKT) and is being developed as a potential treatment for solid and hematological malignancies. Capivasertib is currently in phase 2 of development.

Mechanism of Action

AKT inhibition

Classification

Serine/threonine kinase (AKT) inhibitor

Molecular Target

AKT 1, 2 and 3

Monograph

Capivasertib clinical program is assessing the clinical utility of the agent in a variety of tumor types, in combination with anti-hormonals (breast and prostate) as well as with chemotherapy combinations in a variety of tumor types. These approaches are complimented by a targeted population approach looking at patient segments with activating mutations of the PI3K pathway.

Studies of Interest

Proposals for agent supply support only

Information collaborator would like included in investigator proposals

N/A

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Capivasertib (AZD5363) was originally published by the National Cancer Institute.”

Email